GLP1R and diabetes mellitus: According to the ADA (American Diabetes Association) and the EASD (European Association for the Study of Diabetes) standards of medical care in diabetes (2020), DPP4-inhibitors (DPP4I) and GLP1 receptor agonists (GLP1RA) are recommended as a second-line glucose-lowering agents in cases when patients require combination therapy for achieving adequate glycemic control or when metformin or sulfonylurea therapy is accompanied by episodes of hypoglycemia or another adverse reaction [13,109].